8 Stocks Beating Wall Street's Q2 Targets
AI remains the defining theme for the second quarter earnings season.
Vistagen Therapeutics Inc. (VTGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Commodore Capital Egen Atkinson And Michael Kramarz | 2,788,620 | $630,228 | 0.04% | |
| 2. | Renaissance Technologies Jim Simons | 730,500 | $165,093 | +151% | 0% |
| 3. | Ikarian Capital Neil Shahrestani | 519,077 | $117,311 | 0.01% | |
| 4. | Luminus Management Jonathan Barrett And Paul Segal | 403,115 | $91,104 | +2% | 0.06% |
| 5. | ADAR1 Capital Management Daniel Schneeberger | 351,141 | $79,358 | -54% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.15 | 775,756 | $17,961,078.67 | 1,575,000 | 2023-08-07 | Filing | |
| $0.18 | 100,000 | $17,870.00 | 100,000 | 2022-08-18 | Filing | |
| $0.18 | 100,000 | $17,870.00 | 100,000 | 2022-08-18 | Filing | |
| $0.17 | 300,000 | $50,910.00 | 334,629 | 2022-08-17 | Filing | |
| $0.17 | 600,000 | $103,200.00 | 626,234 | 2022-08-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.89 | 60,000 | $53,400.00 | 20,637,286 | 2022-07-12 | Filing | |
| $3.13 | 30,000 | $93,750.00 | 72,786 | 2021-09-07 | Filing | |
| $0.00 | 4,982,103 | $0.00 | 17,897 | 2011-05-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,574,200 | $355,769 | 0% | |
| 2. | 438,643 | $99,133 | 0.01% | |
| 3. | 415,400 | $95,542 | 0% | |
| 4. | 365,002 | $82,514 | 0% | |
| 5. | 345,432 | $78,068 | 0% |
News See All
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is one of the best psychedelic stocks on our list.
7 Best Psychedelic Stocks to Buy According to Analysts
In this article, we will be taking a look at the 7 Best Psychedelic Stocks to Buy According to Analysts.
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?
We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is also among the best penny stocks.
10 Best Penny Stocks Under $1 According to Hedge Funds
In this article, we will be taking a look at the 10 Best Penny Stocks Under $1 According to Hedge Funds.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2026 Earnings Call Transcript
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2026 Earnings Call Transcript February 12, 2026VistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.51.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2026 Earnings Call Transcript
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2026 Earnings Call Transcript November 13, 2025VistaGen Therapeutics, Inc. misses on earnings expectations.
Vistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety Trial
We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Vistagen Therapeutics, Inc. is one of them. Vistagen Therapeutics, Inc.
13 Best Psychedelic Stocks to Invest in Now
In this article, we will be taking a look at the 13 Best Psychedelic Stocks to Invest in Now.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call Transcript
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call Transcript August 8, 2025 Operator: Good day, everyone, and thank you for standing by.
Hedge Fund Resource Center